
Yaotang Wang
Examiner (ID: 17312, Phone: (571)272-4023 , Office: P/2474 )
| Most Active Art Unit | 2474 |
| Art Unit(s) | 2409, 2419, 3619, 2474 |
| Total Applications | 556 |
| Issued Applications | 416 |
| Pending Applications | 64 |
| Abandoned Applications | 95 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17141684
[patent_doc_number] => 20210309696
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => NEW CONJUGATES OF MONTELUKAST AND PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 16/645355
[patent_app_country] => US
[patent_app_date] => 2019-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24665
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -61
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16645355
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/645355 | Conjugates of montelukast and peptides | Sep 13, 2019 | Issued |
Array
(
[id] => 15990513
[patent_doc_number] => 20200171127
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-04
[patent_title] => METHOD AND PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF DIABETES
[patent_app_type] => utility
[patent_app_number] => 16/567396
[patent_app_country] => US
[patent_app_date] => 2019-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12256
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16567396
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/567396 | METHOD AND PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF DIABETES | Sep 10, 2019 | Abandoned |
Array
(
[id] => 17426875
[patent_doc_number] => 20220054583
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => PEPTIDES AND MEDICAL USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/275029
[patent_app_country] => US
[patent_app_date] => 2019-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7969
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 201
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17275029
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/275029 | PEPTIDES AND MEDICAL USES THEREOF | Sep 10, 2019 | Pending |
Array
(
[id] => 20451865
[patent_doc_number] => 12514909
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Lactate-protected hypoglycemia to treat glycolysis dependent pathological conditions, in particular cancer
[patent_app_type] => utility
[patent_app_number] => 17/270925
[patent_app_country] => US
[patent_app_date] => 2019-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 0
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 166
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17270925
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/270925 | Lactate-protected hypoglycemia to treat glycolysis dependent pathological conditions, in particular cancer | Aug 26, 2019 | Issued |
Array
(
[id] => 19701506
[patent_doc_number] => 12195515
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-14
[patent_title] => HA-1 specific T cell receptors and their use
[patent_app_type] => utility
[patent_app_number] => 17/266258
[patent_app_country] => US
[patent_app_date] => 2019-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 20139
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 186
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17266258
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/266258 | HA-1 specific T cell receptors and their use | Aug 5, 2019 | Issued |
Array
(
[id] => 15666437
[patent_doc_number] => 10597436
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-03-24
[patent_title] => Acylated insulin compound
[patent_app_type] => utility
[patent_app_number] => 16/529095
[patent_app_country] => US
[patent_app_date] => 2019-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6487
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16529095
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/529095 | Acylated insulin compound | Jul 31, 2019 | Issued |
Array
(
[id] => 15493049
[patent_doc_number] => 20200046713
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-13
[patent_title] => TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN
[patent_app_type] => utility
[patent_app_number] => 16/528934
[patent_app_country] => US
[patent_app_date] => 2019-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32860
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16528934
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/528934 | TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN | Jul 31, 2019 | Abandoned |
Array
(
[id] => 16614960
[patent_doc_number] => 20210033613
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => METHODS OF TREATING MULTIFOCAL CANCER
[patent_app_type] => utility
[patent_app_number] => 16/528390
[patent_app_country] => US
[patent_app_date] => 2019-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13122
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16528390
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/528390 | Methods of treating multifocal cancer | Jul 30, 2019 | Issued |
Array
(
[id] => 18717872
[patent_doc_number] => 11795203
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-24
[patent_title] => Protein heterodimer and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/264193
[patent_app_country] => US
[patent_app_date] => 2019-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 20197
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17264193
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/264193 | Protein heterodimer and use thereof | Jul 29, 2019 | Issued |
Array
(
[id] => 15435379
[patent_doc_number] => 20200031873
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-30
[patent_title] => REPURPOSING CELL PENETRATING PEPTIDES AND THEIR NOVEL DERIVATIVES AND IOPROMIDE AND IODO-ARYL CARBONATES FOR TREATMENT OF SENESCENCE-RELATED DISEASES AND DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/526997
[patent_app_country] => US
[patent_app_date] => 2019-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34149
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16526997
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/526997 | REPURPOSING CELL PENETRATING PEPTIDES AND THEIR NOVEL DERIVATIVES AND IOPROMIDE AND IODO-ARYL CARBONATES FOR TREATMENT OF SENESCENCE-RELATED DISEASES AND DISORDERS | Jul 29, 2019 | Abandoned |
Array
(
[id] => 16141461
[patent_doc_number] => 10703792
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-07-07
[patent_title] => Insulin analogues with selective signaling properties and reduced mitogenicity
[patent_app_type] => utility
[patent_app_number] => 16/521969
[patent_app_country] => US
[patent_app_date] => 2019-07-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 10511
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16521969
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/521969 | Insulin analogues with selective signaling properties and reduced mitogenicity | Jul 24, 2019 | Issued |
Array
(
[id] => 16990304
[patent_doc_number] => 20210228724
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-29
[patent_title] => BIOCONJUGATES OF NEUROPEPTIDES DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 17/258701
[patent_app_country] => US
[patent_app_date] => 2019-07-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14699
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17258701
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/258701 | Bioconjugates of neuropeptides derivatives | Jul 17, 2019 | Issued |
Array
(
[id] => 15035677
[patent_doc_number] => 20190328843
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-31
[patent_title] => Calcitonin Analogues for Treating Diseases and Disorders
[patent_app_type] => utility
[patent_app_number] => 16/511815
[patent_app_country] => US
[patent_app_date] => 2019-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9497
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16511815
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/511815 | Calcitonin Analogues for Treating Diseases and Disorders | Jul 14, 2019 | Abandoned |
Array
(
[id] => 19439966
[patent_doc_number] => 12090192
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-17
[patent_title] => Application of RyR2 protein or recombinant RyR2 protein in preparing anti-heart failure medicament
[patent_app_type] => utility
[patent_app_number] => 17/054073
[patent_app_country] => US
[patent_app_date] => 2019-07-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 8
[patent_no_of_words] => 6326
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054073
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/054073 | Application of RyR2 protein or recombinant RyR2 protein in preparing anti-heart failure medicament | Jul 7, 2019 | Issued |
Array
(
[id] => 17035154
[patent_doc_number] => 20210252112
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => PROTEIN-CONTAINING AQUEOUS LIQUID FORMULATION
[patent_app_type] => utility
[patent_app_number] => 17/253458
[patent_app_country] => US
[patent_app_date] => 2019-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9694
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17253458
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/253458 | Protein-containing aqueous liquid formulation | Jun 24, 2019 | Issued |
Array
(
[id] => 17035154
[patent_doc_number] => 20210252112
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => PROTEIN-CONTAINING AQUEOUS LIQUID FORMULATION
[patent_app_type] => utility
[patent_app_number] => 17/253458
[patent_app_country] => US
[patent_app_date] => 2019-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9694
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17253458
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/253458 | Protein-containing aqueous liquid formulation | Jun 24, 2019 | Issued |
Array
(
[id] => 17035154
[patent_doc_number] => 20210252112
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => PROTEIN-CONTAINING AQUEOUS LIQUID FORMULATION
[patent_app_type] => utility
[patent_app_number] => 17/253458
[patent_app_country] => US
[patent_app_date] => 2019-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9694
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17253458
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/253458 | Protein-containing aqueous liquid formulation | Jun 24, 2019 | Issued |
Array
(
[id] => 17035154
[patent_doc_number] => 20210252112
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => PROTEIN-CONTAINING AQUEOUS LIQUID FORMULATION
[patent_app_type] => utility
[patent_app_number] => 17/253458
[patent_app_country] => US
[patent_app_date] => 2019-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9694
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17253458
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/253458 | Protein-containing aqueous liquid formulation | Jun 24, 2019 | Issued |
Array
(
[id] => 17007075
[patent_doc_number] => 20210238236
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => FUSION PEPTIDES OR PROTEINS, THEIR USE, AND SYSTEMS AND KITS BASED THEREUPON, FOR THE SEPARATION AND/OR DETECTION OF PLASTICS, PARTICULARLY OF MICROPLASTICS
[patent_app_type] => utility
[patent_app_number] => 17/253291
[patent_app_country] => US
[patent_app_date] => 2019-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20672
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17253291
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/253291 | FUSION PEPTIDES OR PROTEINS, THEIR USE, AND SYSTEMS AND KITS BASED THEREUPON, FOR THE SEPARATION AND/OR DETECTION OF PLASTICS, PARTICULARLY OF MICROPLASTICS | Jun 20, 2019 | Abandoned |
Array
(
[id] => 17845998
[patent_doc_number] => 11435362
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-06
[patent_title] => Atomic description of immune complex that causes heparin-induced thrombocytopenia
[patent_app_type] => utility
[patent_app_number] => 16/446902
[patent_app_country] => US
[patent_app_date] => 2019-06-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 37
[patent_no_of_words] => 17996
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16446902
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/446902 | Atomic description of immune complex that causes heparin-induced thrombocytopenia | Jun 19, 2019 | Issued |